Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in Patients with Advanced and Recurrent Cervical Cancer Regardless of Bevacizumab Use By Ogkologos - November 25, 2024 869 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the subgroup analysis of the KEYNOTE-826 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Tislelizumab June 7, 2024 Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With... July 20, 2021 PDX Mouse Models Are Reliable Stand-Ins for Human Tumors, Study Finds February 2, 2021 Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line... June 25, 2025 Load more HOT NEWS Celebrating 10 years of partnership with NIVEA Sun Grandma Saves Her Money To Put Up A Billboard For Everyone... What to Know About Navigating Cancer Care With a Disability: An... Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients...
